XSpray and Cerbios-Pharma announce partnership on the use of XSpray’s RightSize(TM) technology
Stockholm, Sweden – September 4, 2012. XSpray Microparticles AB today announced a partnership with Cerbios-Pharma SA of Lugano, Switzerland for the joint development of HPAI (High Potency Active Ingredients). HPAI development will be provided by XSpray in Stockholm, while the cGMP production for clinical and commercial use will be carried out at Cerbios in Lugano.
“We are very pleased with this partnership. We believe that RightSize™ technology offers significant advantages in the development of HPAIs”, commented XSpray’s CEO, Dr. Per Andersson. “This partnership is an important step towards the development of HPAIs with unique characteristics.”
The formulation and manufacturing abilities of XSpray’s RightSize technology offer the opportunity to improve drug substances through various strategies, enabling full control over particle design and production – simplifying drug formulation, extending delivery options and allowing the addition of innovative properties that truly benefit patients.
RightSize technology not only provides a superior process to traditional methods. It can also be effectively scaled from discovery scale up to production volumes, making it an important breakthrough in the manufacture of pharmaceutical particles using supercritical fluid technology.
One of the advantages of this technology is that the moderate temperatures used make it ideal for particle size reduction of thermolabile compounds.
“We are enthusiastic about this partnership with XSpray. Access to RightSize technology will strengthen our API development and manufacturing for third parties”, says Dr. Gabriel Haering, CEO of Cerbios. “Through the use of this innovative technology for HPAIs, Cerbios will be able to offer a unique capability, enabling the generation not only of particles having narrow particle size distribution but also different crystal forms and/or polymorphs up to the full control of particle design, including solid state form. In combination with other technologies available at Cerbios it will generate intellectual property that will definitely help our partners in their success.”
Financial terms for access to XSpray’s RightSize technology and expertise will not be disclosed.
For further information please contact:
| Cerbios-Pharma SA Andrea Tam Director Business Development andrea.tam@cerbios.ch |
XSpray Microparticles AB Karen Frost Marketing Director karen.frost@xspray.com |
About Cerbios-Pharma SA
Cerbios is a privately held self-financed company located in Lugano (Switzerland) specialized in the development and manufacturing of chemical and biological APIs for partners world-wide.
APIs made by Cerbios cover small molecules (Chemical Division), biopharmaceuticals including Monoclonal Antibodies, Recombinat Proteins and Probiotics (Biological Division).
Services for third parties under exclusive manufacturing are offered in the area of HPAIs for the Chemical Division and Monoclonal Antibodies and Recombinant Proteins for the Biological Division.
Full CMC support is provided to partners in order to provide them with the supply of cGMP clinical batches, registration/validation material and APIs from commercial manufacturing. Paramount to this is the supply of all documentation required for a successful registration.
About XSpray
XSpray Microparticles AB is a drug delivery company with a cutting-edge, scaleable platform technology – RightSize™ technology - and an in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process.
XSpray Microparticles has its headquarters and development laboratories in Stockholm, Sweden, and offers GMP production at a state-of-the-art manufacturing facility.
XSpray’s RightSize technology, innovations and the extensive expertise of employees and specialist partners are available through partnering activities. Contact XSpray to find out more